Company Interview / From Australia to America Orthocell heals and expands

OrthoCell (ASX:OCC) is entering a dynamic growth phase, according to Paul Anderson, as the company gains momentum with the US launch of its flagship nerve repair product, Remplir. The collagen-based medical device, designed to reduce surgical time and increase consistency in nerve repair procedures, has received FDA approval and is approaching its first 100 cases in the US. Anderson highlights the company’s careful focus on building a robust distribution network along the eastern seaboard, with a direct sales team driving adoption in major US centres. Despite tariff challenges, he states that OrthoCell’s resilient manufacturing process and supply chain position the company well for ongoing success.

Remplir’s clinical applications are expanding, with recent adoption in prostate surgery in Australia, supporting patients with continence and erectile function after radical prostatectomy. Anderson notes that this growth is organic, driven by strong surgeon uptake, and adds substantially to OrthoCell’s addressable market both locally and abroad. The company is also seeking regulatory approvals in the EU and UK, leveraging the success of its Striate Plus bone regeneration product, which already holds MDR certification in Europe.

Anderson maintains a positive outlook for revenue growth, pointing to record quarters and significant untapped potential in the US. Future development includes tendon repair products, while strategic investments such as the increased stake in Marine Biomedical are creating synergies in bone grafting solutions.

You should be aware that companies presenting do so under commercial agreement with AUSBIZ CAPITAL PTY LTD